Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 1999

View Archived Issues

Novel echinocandin B tested in neutropenic rabbit model of disseminated candidiasis

In vivo antiangiogenic activity described for FMPA

Company Profile: AtheroGenics

Aurora Biosciences announces two new collaborations with Merck

COX-2 inhibitors: pros and cons debated in current literature

Teva signs letter of intent to acquire Novopharm

Very promising clinical trial results achieved with leukemia treatment

Hollis-Eden reports preliminary results from phase I/II HIV trial in South Africa

Factor Xa inhibitors described by Merck

New series of uroselective alpha1-adrenoceptor antagonists in development at Abbott

Cannabinoids with selectivity for CB2 receptor designed at U.S. university

GABA-A receptor agonists/inverse agonists disclosed by Dainippon

Novel hematinic agent SB-251353 has synergistic effects with G-CSF in preclinical models

Neuroprotective profile of new AMPA/kainate antagonist presented at Neuroscience meeting

Hughes Institute's COBRA compounds target a novel tubulin binding site

Pyridazinone cell adhesion inhibitors investigated as promising antiinflammatory agents

MR-2917: centrally acting muscle relaxant with reduced side effects

Optical resolution of TAN-67; analgesic activity resides in (-)-enantiomer

Gilead terminates U.S. development of adefovir dipivoxil for HIV

News flash: highlights from the AstraZeneca pipeline review

Neuroprotective use-dependent blocker of voltage-dependent Na+ channels, BIII-890-CL

Calpain inhibitor BDA-410 exerts neuroprotective effects in preclinical models

News from ASH: Hemolink performs extremely well in phase II trial in CABG patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...